Global Gaucher Disease Treatment Market Size, Competitive Analysis, Share, Forecast- 2019-2025

The global Gaucher disease treatment market is anticipated to grow at a considerable CAGR of around 3% during the forecast period. Gaucher disease is a type of genetic disease caused by mutation of cells that leads to one of the enzymes in the body not working properly. The body constantly recycles itself as old cells die and new cells are made There is a long list of enzymes that are responsible for the recycling dead cells, one of which when it's not working properly leads to Gaucher disease. Gaucher disease has a lot of different symptoms out of which the most common is an enlarged liver and spleen. Currently, quite a lot of research is going on in the field regarding the treatment of Gaucher disease, which in turn, fueling the growth of the Gaucher disease treatment market.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/gaucher-disease-treatment-market

However, the SBT causes any adverse reaction in patients ranging from weight loss, tremor, flatulence, abdominal pain, dyspepsia, paresthesia, influenza-like symptoms, visual disturbances, and thrombocytopenia which is lowering the popularity of SBT in the Gaucher disease market. In addition, the high cost associated with the treatment is limiting the growth of the global Gaucher disease treatment market. For instance, according to the National Institute of Health in 2018, the average wholesale prices of ERTs are $1,903 per vial for imiglucerase (400 units), $1,652 per vial for velaglucerase (400 units), and $935 per vial for taliglucerase (200 units). Patients are often administered 60 units/kg every two weeks. As this dosage, the approximate annual costs for imiglucerase, velaglucerase, and taliglucerase would be $544,260, $472,475, and $510,510, respectively.

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/gaucher-disease-treatment-market

Market Segmentation

Gaucher Disease Treatment Market by Disease Type

Type I
Type II
Type III
Gaucher Disease Treatment Market by Treatment Type

Enzyme Replacement Therapy (ERT)
Substrate Reduction Treatment (SBT)
Regional Analysis

North America

US
Canada
Europe

UK
Germany
Italy
Spain
France
Rest of Europe
Asia-Pacific

China
India
Japan
Rest of Asia-Pacific
Rest of the World

Company Profiles

AVROBIO, Inc.
Amicus Therapeutics
CENTOGENE N.V.
ERAD Therapeutics Inc.
Genzyme Corp. (Sanofi Company)
Greenovation Biotech GmbH
JCR Pharmaceuticals Co., Ltd.
Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
Lixte Biotechnology Holdings, Inc.
Novartis International AG
ORPHAZYME A/S
Oxyrane
Pfizer Inc.
Protalix BioTherapeutics, Inc.
Takeda Pharmaceutical Co. Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/gaucher-disease-treatment-market



About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.